Highlights

  • Consensus rating of Buy from 13 analysts: 11 Buy or equivalent, 2 Hold, 0 Sell or equivalent.
  • Mean price target of A$2.98 against a share price of A$2.13 on 8 October 2026, an implied upside of 40.0%.
  • Analyst targets range from A$2.24 to A$3.70.
  • Revenue and other income were $788.7 million, up 25.6%.

Integral Diagnostics (ASX:IDX) carries a consensus analyst rating of Buy. Of the 13 analyst recommendations recorded, 11 are Buy or equivalent, 2 are Hold and 0 are Sell or equivalent. The mean price target is A$2.98, with targets ranging from A$2.24 to A$3.70, against a current share price of A$2.13 (8 October 2026). Integral Diagnostics Limited is a medical imaging and radiology services provider operating clinics and hospital-based services across Australia and New Zealand.

Company name

Integral Diagnostics

Ticker

(ASX:IDX)

Exchange

ASX (Australian Securities Exchange)

Current share price

A$2.13

Price date

8 October 2026

Number of analysts

13

Rating consensus

Buy

Consensus price target (mean)

A$2.98

Highest target

A$3.70

Lowest target

A$2.24

Implied upside/downside to mean target

Implied upside of 40.0%

Latest developments

Integral Diagnostics (ASX:IDX) announced its FY26 results for the year ended 30 June 2026 on 25 August 2026, consistent with its unaudited preliminary results of 10 August 2026. Revenue and other income were $788.7 million, up 25.6%. Operating EBITDA was $164.8 million, up 30.3%, with the Margin up 80 basis points to 20.9%. Operating NPAT was $47.4 million, up 50.1%, and operating diluted EPS were 12.6 cents, up 23.6%. Statutory NPAT was $22.0 million, after $25.4 million of transaction, integration and restructuring costs, contingent consideration remeasurement and related share-based expenses, net of tax.

Operating free Cash Flow was $106.4 million, up 30.7%, and cash flow conversion was 82.0%. Net Debt to operating EBITDA was 2.3 times, down from 2.6 times at 30 June 2025. The final fully Franked Dividend is 6.0 cents per share, up 50.0%, payable on 2 October 2026, taking the total FY26 fully franked dividend to 9.3 cents per share.

Sector context

The company operates in diagnostic imaging, where revenue growth in FY26 reflected a full year of the merged group following its major transaction and integration activity. Its results are expressed on an operating basis that excludes transaction and integration costs, which the company reports separately.

Risks and what to watch

Statutory NPAT of $22.0 million was well below operating NPAT of $47.4 million because of $25.4 million of transaction and integration related items. Revenue growth reflects the full-year effect of the merger, so comparisons with FY25 include that scale change. Net debt to operating EBITDA is 2.3 times, and imaging Earnings depend on referral volumes, Medicare funding settings and labour costs.

Next milestones

Items to watch include payment of the final dividend on 2 October 2026, further integration progress, Leverage relative to 2.3 times, cash conversion, and the half-year result.